IDH2 mutation

Suehara- whole exome seq of PTCL reveals subtype of AITL - C3 • more IDH2 mutation / chrom 5 gain / mutational burden • more inflammatory clin characteristics • worse prog than other AITL #17ICML (@graham74GC)

Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023 - setting = residual or recurrent disease - primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6) Here are some toughts 🧵 1/6 (@Timothee_MD)

65-70 year old fit patient diagnosed with “MDS” in community due to 15% blasts in diagnostic BM Bx. NGS results NPM1, DNMT3A and IDH2 mutations c/w AML. Received 1 cycle of Aza in community before seeing you. Blood counts stable w/o circulating blasts. You recommend? (@LeukDocJZ)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation https://t.co/eLOcMyAYqx The diagnostic IDH mutation status in AML did not significantly influence outcomes following HSCT #leusm #AML (@TalhaBadarMD)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial | Blood | American Society of Hematology https://t.co/hzoajGRm7G (@SCTNB)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial https://t.co/L3TP62lPks ➡️ Modest benefit compared to CCR (HMA, LDAC, IDAC); would be more difficult to replicate OS benefit in pts with prior Ven Rx (@TalhaBadarMD)

P3 study of #enasidenib vs CCR in #IDH2 mutated r/r #AMLsm @BloodJournal 👉🏻 better ORR 👉🏻 ⬆️ EFS 👉🏻 🚫 impact on OS Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial https://t.co/6J0vwrTyp9 (@AlkaliDr)

Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations https://t.co/4PFbwTurci #AML #ASH22 (@smbenlazar)

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant #AML Patients: 3-Year Follow-up https://t.co/QUILQEfbk1 #ASH22 (@smbenlazar)

Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia https://t.co/V1fZGadcpA #AML #ASH22 (@smbenlazar)

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up #Leukemia #ASH22 #MedTwitter #MedEd (@Abdallah81MD)

'Precision medicine': pathogenic insights essential for design of clinical trials Follicular helper T-cell (TFH) lymphoma: common genetic landscape TET2: 80% +/- DNMT3A 35% In many develops on background of clonal hematopoiesis RHOAG17V, IDH2R172 mutations ⁦@Hememachine⁩ (@CwynKate)

'Precision medicine': pathogenic insights essential for design of clinical trials Follicular helper T-cell (TFH) lymphoma: common genetic landscape TET2: 80% +/- DNMT3A 35% In many develops on background of clonal hematopoiesis RHOAG17V, IDH2R172 mutations @Hememachine (@CwynKate)

🔥Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in #cholangiocarcinoma🔥 @Nature_NPJ https://t.co/ddGOZ1PboG 👉Option for sequential mIDHi to overcome acquired resistance mutations @myESMO @OncoAlert @EASLedu @enscca (@ArndtVogel)

IDH2 mutants are (in Yorkshire) weird. I had one (big, pleomorphic ugly-ass cells) that was IDH2mt, and co deleted. Was tempted to call it "pleomorphic oligodendroglioma" or similar. Another IDH2 mutant was an oligo harbouring a met. (@JRobinHighley)

Ivosidenib resistance in cholangio can be caused by development of a: 1. Oncogenic IDH2 mutation 2. Secondary IDH1 mutation The IDH1 mutation D279N causes ivosidenib resistance by blocking ivosidenib-IDH1 binding. The IDH1 inhibitor LY3410738 can overcome this resistance. (@JamesClearyMD)

Enasidenib works but it’s not a game changer. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial | Blood | American Society of Hematology https://t.co/djCFjTd5gA (@AaronGoodman33)

Leukemia Question A 72 year old with IDH2 mutated AML (no other mutations) and normal karyotype achieves a CR to venetoclax plus azacitidine. His performance status is good and a 10/10 MUD is available. You recommend… (@AaronGoodman33)

The use of IDH inhibitors as a bridge to allo-HCT in patients with relapsed or refractory AML with IDH1 or IDH2 mutation is an effective strategy. ✅CR before HCT: 55% ✅ 2-year OS: 100% ✅ 3-year OS: 86% Full article👉🏼 https://t.co/xKddCbq53X Cc @alexis_genthon @Mohty_EBMT (@RemyDulery)

TFR in AML with HMA + venetoclax. Interesting data for select group of patients with NPM1 and/or IDH2 mutation. https://t.co/O1ICV4O6h6 @AML_Hub (@salmanf)

I wish I knew the answer to this. I also wish I knew the answer as to why IDH1 and IDH2 mutated AML have quite differing outcomes despite appearing to have similar genomic and clinical characteristics. (@CLachowiez)

What is best frontline Rx for IDH2 mutated AML- read more in @ASHClinicalNews about the Enasidenib Plus Azacitidine Combo Improved Response Rates in Newly Diagnosed IDH2-mutated AML & my commentary. https://t.co/uTR6JPojM4 (@beatalleukemia)

A 56 y/o man w/ #AML (trisomy 8, mutations in ASXL1, SRSF2, IDH2, RUNX1) declined conventional therapy but achieved remission after 7 Kambô treatments (topical application of Phyllomedusa bicolor frog secretions). Which do you think is the most likely? https://t.co/0cm79uglGj (@DavidSteensma)

Is it AML (MRC)? Do you have karyotype & NGS results yet? Ven aza works magic in NPM1/IDH2/IDH1 mutatedAML. If TP53 with or complx CG then chemo might be a better option. Re: fitness, I’m a fan of frailty assessment and I use it religiously. AML composite index is a good tool :) (@dgkhalaf)

Current Treatment Algorithms. Acute myeloid leukemia with IDH1 or IDH2 mutations. @DrHKantarjian @MDAndersonNews #BCJCTA #OpenAccess https://t.co/ydWHCASbHq (@BloodCancerJnl)

Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells - ScienceDirect https://t.co/jN7cN7ISAb (@weldeiry)

Recent Review by Claudio Cerchione (@DottorClaudio), Hagop Kantarjian (@DrHKantarjian) and colleagues, look at metabolic deregulation in #AML and new strategies for tailored therapy targeting mutations in IDH1 and IDH2. Read more ➡️ https://t.co/oobKxndXM7 (@FrontOncology)

🔦Spotlight #CE! 🆓#CME #CPE featuring @DanPollyea View▶️https://t.co/dkRSUtbQuO 🏷️Mutational testing🔛IDH mutations during prognosis of #AML 🏷️Implications of IDH/IDH2 mutations🔛prognosis & tx 🏷️Clinical trials of IDH1/IDH2 inhibitors #MEdEd #MedTwitter #SoMe (@MediComOncology)

Spotlight 🔛🆓#CME #CPE w/ @DanPollyea View▶️https://t.co/dkRSUtbQuO 🏷️Mutational testing🔛IDH mutations during prognosis of #AML 🏷️Implications of IDH/IDH2 mutations🔛prognosis & tx 🏷️Clinical trials of IDH1/IDH2 inhibitors #MEdEd #MedTwitter #cancer #SoME (@MediComOncology)

🔦Spotlight #CE! 🆓#CME #CPE featuring @DanPollyea View▶️https://t.co/dkRSUttrmm 🏷️Mutational testing🔛IDH mutations during prognosis of #AML 🏷️Implications of IDH/IDH2 mutations🔛prognosis & tx 🏷️Clinical trials of IDH1/IDH2 inhibitors #MEdEd #MedTwitter #SoMe (@MediComOncology)

Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant #Sarcoma | ⁦@ASCO_pubs⁩ Precision Oncology https://t.co/Chpic8roaW (@JTrentMDPhD)

Tune in to #TumorBoardTuesday this Tuesday, February 23rd at 6 pm MST with @rachnatshroff. She will present a case of #cholangiocarcinoma with: An FGFR fusion AND an IDH2 mutation (@curecc)

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated AML: Phase 2/1b Sub-Study of the Beat AML Master Trial by Dr Eytan M. Stein #ASH20 @Mohty_EBMT #ASHRM (@razan_mohty)